Overview


According to FutureWise analysis the market for dry age-related macular degeneration in 2023 is US$ 1.63 billion, and is expected to reach US$ 3.2 billion by 2031 at a CAGR of 8.80%.

Global, age-related macular degeneration is the leading cause of severe visual impairment and disability in older adults. This review focuses on current trends in the development of new therapies targeting specific pathophysiological pathways in dry aged-related macular degeneration. It is expected that improving our understanding of the complex mechanisms of dry aged-related macular degeneration will help to address this largely unmet clinical need. The development of the global dry Age-related Macular Degeneration market is attributed to the growth of geriatric populations and their growing prevalence of age-related macular degeneration, as well as the development of new treatment techniques for dry Age-related macular degeneration combined with the increasing number of clinical trials for dry age-related macular degeneration. Variables like expanding medical services use will probably aid the market's development. Growing geriatric populations and the rise in dry age-related macular degeneration are driving the global market expansion.

The disease progresses gradually to cause severe vision loss in the central vision. Early signs of age-related macular degeneration, specifically age-related maculopathy, include extracellular deposits, subretinal deposits of oxidized lipids and proteins beneath the retinal pigment epithelium, and variable quantities of visible clumps of pigment in the macula. During the intermediate stages of age-related macular degeneration(AMD), drusen become larger and pigmentary changes become more severe. As AMD progresses, patients develop either subretinal choroidal neovascularization or non-neovascular "dry" AMD. Macular degeneration caused by aging leads to irreversible blindness and loss of vision. According to the National Institute on Aging, up to one third of individuals aged 75 and older have AMD. Researchers would surely benefit from genome-wide association studies in order to enhance their understanding of the genetics of complex diseases including AMD and to develop targeted treatments to prevent or treat it. Obtaining valuable information on epigenetic regulation of AMD will require further research.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Dry Age-Related Macular Degeneration Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Dry Age-Related Macular Degeneration Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Santen Pharmaceuticals Inc
  • Allergan plc
  • Bausch Health
  • Alimera Science Inc
  • Phio Pharmaceuticals Corp
  • Ocumension Therapeutics Co. Ltd
  • Belite Bio Inc
  • Kubota Vision Inc
  • Iveric Bio
  • Eyestem Research Pvt Ltd
  • Yuyang DNU Co., Ltd
  • Stealth Biotherapeutics Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Stages

  • Early AMD
  • Intermediate AMD
  • Late AMD

By Age Group

  • Above 40 Years
  • Above 60 Years
  • Above 75 Years

By Diagnosis & Treatment

  • Treatment
    • Nutrition Therapy
    • Antioxidants
      • Vitamins
      • Zinc
      • Copper
      • Omega-3 fatty acids
      • Others
    • Telescopic Lens Implant
    • Others
  • Diagnosis
    • Fluorescein Angiogram
    • Preliminary Test
    • Optical Coherence Tomography
    • Others

By Route of Administration

  • Oral
  • Injectables

By End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Academic Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Dry Age-Related Macular Degeneration Market By Stages, By Age Group, By Diagnosis & Treatment, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions 

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Dry Age-Related Macular Degeneration Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Dry Age-Related Macular Degeneration Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Dry Age-Related Macular Degeneration Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Dry Age-Related Macular Degeneration Market, By Stages Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Early AMD
        2. Intermediate AMD
        3. Late AMD

  • 8.   Dry Age-Related Macular Degeneration Market, By Age Group Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Above 40 Years
        2. Above 60 Years
        3. Above 75 Years

  • 9.   Dry Age-Related Macular Degeneration Market, By Diagnosis & Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Treatment
         1.1. Nutrition Therapy
         1.2. Antioxidants
          1.2.1. Vitamins
          1.2.2. Zinc
          1.2.3. Copper
          1.2.4. Omega-3 fatty acids
          1.2.5. Others
         1.3. Telescopic Lens Implant
         1.4. Others
        2. Diagnosis
         2.1. Fluorescein Angiogram
         2.2. Preliminary Test
         2.3. Optical Coherence Tomography
         2.4. Others

  • 10.   Dry Age-Related Macular Degeneration Market, By Route of Administrations Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Oral
        2. Injectables

  • 11.   Dry Age-Related Macular Degeneration Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals and Clinics
        2. Diagnostic Centers
        3. Academic Research Institutes
        4. Others

  • 12.   North America Dry Age-Related Macular Degeneration Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 13.   Latin America Dry Age-Related Macular Degeneration Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 14.   Europe Dry Age-Related Macular Degeneration Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 15.   Asia Pacific Dry Age-Related Macular Degeneration Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 16.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Santen Pharmaceuticals Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bausch Health
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Alimera Science Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Phio Pharmaceuticals Corp
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Ocumension Therapeutics Co. Ltd
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Belite Bio Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Kubota Vision Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Iveric Bio
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Eyestem Research Pvt Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Yuyang DNU Co., Ltd
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
         12. Stealth Biotherapeutics Inc
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients